Compare MasterCard Inc (MA) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasterCard Inc vs State Street SPDR S&P Biotech ETF — how do they compare? MasterCard Inc trades at $538.19 (market cap $483.71B), while State Street SPDR S&P Biotech ETF trades at $154.41. The key difference: MasterCard Inc pays a 0.64% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, MasterCard Inc nearer its low. Which is the better fit depends on your goals.
| MA | XBI | |
|---|---|---|
Market Cap | $483.71B | — |
Volume | 4,635,698 | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $598.96 | $164.28 |
52-Week Low | $471.55 | $85.16 |
Enterprise Value | $494.45B | — |
Dividend Yield | 0.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $538.30, down 0.97% on the day, with a bullish technical outlook supported by moving averages and strong price targets. The company demonstrates robust fundamentals with revenue growth from $32.79B in 2025 to a projected $33.9B in 2026, net income margins above 45%, and consistent earnings beats. Recent news highlights institutional buying and strategic initiatives in AI and financial inclusion.
The outlook remains positive given Wall Street's strong buy consensus and a $634.27 price target, though high valuation multiples and competitive disruption from new payment technologies present risks. Earnings growth and market leadership are key catalysts for upside.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
